Newsletter Archive

1. 06.18.26 -- Reduce mAb Aggregates: Practical Strategies 6/18/2026

   06/18/26 Life Science Leader Newsletter

2. 06.17.26 -- Five Reasons The Hub-And-Spoke Model Is Gaining Traction In Biotech 6/17/2026
   06/17/26 Life Science Leader Newsletter
3. 06.14.26 -- The Biotech Hub-And-Spoke Model Comes Of Age 6/14/2026
   06/14/26 Life Science Leader Newsletter
4. 06.13.26 -- Life Science Leader Newsletter - Best Of May 6/13/2026
   06/13/26 Life Science Leader Newsletter
5. 06.11.26 -- New Insights Into ADC Analytical Strategies And Payload Innovation 6/11/2026

   06/11/26 Life Science Leader Newsletter

6. 06.08.26 -- Smarter Clinical Trials Start With Better Strategy 6/8/2026
   06/08/26 Life Science Leader Newsletter
7. 06.07.26 -- Repurposed And Derisked Development Candidates As Industry Innovation 6/7/2026
   06/07/26 Life Science Leader Newsletter
8. 06.05.26 -- Rare Disease Drug Commercialization With Zevra Therapeutics' Neil McFarlane 6/5/2026
   06/05/26 Life Science Leader Newsletter
9. 06.05.26 -- New Podcast Episodes: Validation Challenges, Rare Disease Drug Commercialization, Redefining CAR-T Timing, and More 6/5/2026
   06/05/26 Life Science Leader Newsletter
10. 06.04.26 -- Who Are Clinical Trials Really Reaching? 6/4/2026

    06/04/26 Life Science Leader Newsletter